Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction

Korean Journal of Internal Medicine

Volumn 28, Issue 2, 2013, Pages 165-173

  Guzel, Savas ^a   Serin, Ozden ^b   Guzel, Eda Celik ^a   Buyuk, Banu ^b   Yilmaz, Güzin ^c   Güvenen, Guvenc ^d  

^a NAMIK KEMAL UNIVERSITY   (Turkey)

^b ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c Diyarbakir Devlet Hastanesi   (Turkey)

^d Diyarbakir State Hospital ^*  (Turkey)

Author keywords

Inflammation; Interleukin 33; Matrix metalloproteinase 9; Myocardial infarction

Indexed keywords

ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; CREATINE KINASE MB; FIBRINOGEN; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 33; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; TROPONIN T; AUTACOID; BIOLOGICAL MARKER; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MMP9 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CREATINE KINASE BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; TIME;

ADULT; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKINS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84875492228     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2013.28.2.165     Document Type: Article

References (40)

1. Ross R. Atherosclerosis: an inf lammatory disease. N Engl J Med 1999;340:115-126.
2. Libby P. Inf lammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83:456S-460S.
3. Li JJ. Inflammation: an important mechanism for different clinical entities of coronary artery diseases. Chin Med J (Engl) 2005;118:1817-1826.
4. Myllarniemi M, Calderon L, Lemstrom K, Buchdunger E, Hayry P. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J 1997;11:1119-1126.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
6. Brauer PR. MMPs: role in cardiovascular development and disease. Front Biosci 2006;11:447-478.
7. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001;89:1092-1103.
8. Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inf lammatory cytokines. Circulation 2002;106:3024-3030.
9. Lacraz S, Nicod L, Galve-de Rochemonteix B, Baumberger C, Dayer JM, Welgus HG. Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest 1992;90:382-388.
10. Lijnen HR. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003;33:275-281.
11. Hirohata S, Kusachi S, Murakami M, et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997;78:278-284.
12. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-372.
13. Etoh T, Joffs C, Deschamps AM, et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 2001;281:H987-H994.
14. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001;89:201-210.
15. Dinh W, Futh R, Scheffold T, et al. Increased serum levels of tissue inhibitor of metalloproteinase-1 in patients with acute myocardial infarction. Int Heart J 2009;50:421-431.
16. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-490.
17. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008;52:2166-2174.
18. Kuchler AM, Pollheimer J, Balogh J, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinf lammatory activation. Am J Pathol 2008;173:1229-1242.
19. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-1549.
20. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205:339-346.
21. Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circ Res 2002;90:1039-1040.
22. Laurat E, Poirier B, Tupin E, et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001;104:197-202.
23. Pinderski LJ, Fischbein MP, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002;90:1064-1071.
24. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
25. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-1569.
26. Kim SH, Kang YJ, Kim WJ, et al. TWEAK can induce pro-inf lammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004;68:396-399.
27. Kalela A, Koivu TA, Sisto T, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002;62:337-342.
28. Kaden JJ, Dempf le CE, Sueselbeck T, et al. Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction. Cardiology 2003;99:140-144.
29. Higo S, Uematsu M, Yamagishi M, et al. Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection. Circ J 2005;69:1180-1185.
30. Romanic AM, Burns-Kurtis CL, Gout B, Berrebi-Bertrand I, Ohlstein EH. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci 2001;68:799-814.
31. Kameda K, Matsunaga T, Abe N, et al. Increased pericardial fluid level of matrix metalloproteinase-9 activity in patients with acute myocardial infarction: possible role in the development of cardiac rupture. Circ J 2006;70:673-678.
32. van den Borne SW, Cleutjens JP, Hanemaaijer R, et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2009;18:37-43.
33. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-217.
34. Tziakas DN, Chalikias GK, Hatzinikolaou EI, et al. N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol 2005;96:31-34.
35. Nanni S, Melandri G, Hanemaaijer R, et al. Matrix metalloproteinases in premature coronary atherosclerosis: inf luence of inhibitors, inf lammation, and genetic polymorphisms. Transl Res 2007;149:137-144.
36. Tan J, Hua Q, Gao J, Fan ZX. Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008;31:413-418.
37. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-2966.
38. McLaren JE, Michael DR, Salter RC, et al. IL-33 reduces macrophage foam cell formation. J Immunol 2010;185:1222-1229.
39. Mehta JL, Saldeen TG, Rand K. Interactive role of infection, inf lammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998;31:1217-1225.
40. Shishehbor MH, Bhatt DL. Inflammation and atherosclerosis. Curr Atheroscler Rep 2004;6:131-139.